Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 15:59:55 17/05/2024 BST			5-day change	1st Jan Change
903.3 ^DKK	-1.05%		+2.28%	+29.39%

05-17	Roche: share price stands out, Deutsche Bank in support	CF
05-16	Health Care Flat as Momentum Wanes -- Health Care Roundup	DJ

NOVO NORDISK : Berenberg reiterates its Neutral rating

May 08, 2024 at 03:11 pm

Berenberg confirms his opinion on the stock and remains Neutral. The target price is unchanged at DKK 900.

Latest news about Novo Nordisk A/S

Roche: share price stands out, Deutsche Bank in support	05-17	CF
Health Care Flat as Momentum Wanes -- Health Care Roundup	05-16	DJ
Novo Nordisk Reports Fire Incident at Under-Construction Facility in Kalundborg, Denmark	05-16	MT
Novo Nordisk Building Under Construction at Manufacturing Hub in Denmark Hit by Fire	05-16	MT
India's Biocon posts Q4 profit fall as higher raw material costs bite	05-16	RE
NOVO NORDISK: FIRE AT KALUNDBORG SITE HAS NO IMPACT ON EXISTING…	05-16	RE
Novo Nordisk building site hit by fire, Danish TV2 reports	05-16	RE
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial -- Update	05-16	DJ
Roche Gains as Weight-loss Injection Shows Potential in Early-stage Study	05-16	MT
Roche shares gain on obesity drug results from early-stage trial	05-16	RE
US Senate Committee Warns of Potential Healthcare Bankruptcy Due to Novo Nordisk's Wegovy	05-16	MT
Health Care Up on Momentum -- Health Care Roundup	05-15	DJ
Sector Update: Health Care Stocks Advance Late Wednesday Afternoon	05-15	MT
Sector Update: Health Care	05-15	MT
Novo Nordisk Weigh-Loss Drugs Could Bankrupt US Health Care, Senate Committee Report Says	05-15	MT
UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down	05-15	RE
Novo Nordisk Owner to Buy Controlling Stake in Single Use Support	05-15	MT
NOVO NORDISK : UBS sticks Neutral	05-15	ZD
Health Care Up on Improved Risk Appetite -- Health Care Roundup	05-14	DJ
Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs	05-14	RE
Novo Nordisk's Wegovy Reduces Cardiac Events, Sustains Weight Loss, New Analysis Shows	05-14	MT
Novo Nordisk Selling $5 Billion in Bonds to Back Catalent Deal	05-14	MT
NOVO NORDISK : JP Morgan reaffirms its Buy rating	05-14	ZD
NOVO NORDISK : UBS reaffirms its Neutral rating	05-14	ZD
Stifel Lifts Novo Nordisk PT, Keeps Buy Recommendation	05-14	MT

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Novo Nordisk CEO: Demand for Wegovy outstrips supply

May 02, 2024 at 05:36 pm

NOVO NORDISK : Q1 beat; guidance upgrade but sentiment nonetheless dampened by price reductions

May 02, 2024 at 05:09 pm

Novo Nordisk doesn't disappoint

January 31, 2024 at 03:48 pm

More Strategies

Ratings for Novo Nordisk A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

903.3 DKK

Average target price

909.2 DKK

Spread / Average Target

+0.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+29.39%	584B
ELI LILLY AND COMPANY	+32.09%	693B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B
PFIZER, INC.	-0.52%	162B

Other Pharmaceuticals

Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

NOVO NORDISK : Berenberg reiterates its Neutral rating

Latest news about Novo Nordisk A/S

Chart Novo Nordisk A/S

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novo Nordisk A/S

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals